Transforming treatment decisions with clinically actionable insights
Now approved for patients in all 50 states, including New York — The Oncology Hotspot assay detects actionable variants in advanced solid tumor cancer to help clinicians personalize and optimize cancer therapy.
Highly SensitiveThe power to detect variants down to 5% allele fraction.
ActionableIdentifies clinically-actionable variants in 50 genes to help optimize treatment planning.
PreciseAnalyzes specific variants within 207 regions of the genome known to be associated with cancer diagnosis, prognosis, and treatment response.
Analyzes 50 key cancer genes
The Oncology Hotspot Panel screens for clinically actionable variants in 50 genes, including BRAF, EGFR, KRAS, and PIK3CA.
How to order the Oncology Hotspot Panel
Complete a requisition form. Please note that this test may only be ordered by healthcare providers.
Submit a specimen for testing. The desired specimen for this assay is nine unstained glass slides and one H&E stained glass slide. Please note that we require a tumor specimen submission to contain at least 20% tumor cells to account for tumor heterogeneity.
The sample is sequenced using multiplex PCR and next-generation sequencing technologies.
Our molecular pathologists and geneticists complete an expert review and clinical utility interpretation of any variants that are identified.
A comprehensive results report is provided by fax 10 to 21 days after the accessioning of the sample. If you have any questions about the report, our board certified pathologists and geneticists are available to help.